Acylsulfonamide KAT6A Inhibitors for Enzyme Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for compounds and compositions that can effectively target and inhibit KAT6A or KAT6B target proteins to treat proliferative disorders and autoimmune diseases, as there are currently no FDA-approved therapeutics for these targets.
Innovation Solution
Development of acylsulfonamide compounds represented by Formula (J) and their pharmaceutically acceptable salts, which act as KAT6A inhibitors, potentially treating diseases mediated by KAT6A.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule compounds are developed to target KAT6A/KAT6B proteins, then therapeutic efficacy for proliferative disorders and autoimmune diseases is improved, but device complexity and manufacturing challenges increase due to the novel target and lack of FDA-approved therapeutics
Solution Approach 1:
The patent employs parameter changes by systematically varying substituents at multiple positions (R1, R2, R3, R4, n, q) in the acylsulfonamide core structure to optimize KAT6A/KAT6B binding affinity and selectivity. This allows tuning of molecular properties to achieve therapeutic efficacy while managing structural complexity through controlled variation rather than complete structural redesign
Solution Approach 2:
The acylsulfonamide compounds are designed to target both KAT6A and KAT6B proteins with a single molecular scaffold, providing multi-functionality against related targets. This universal approach addresses the need for therapeutics against proliferative disorders and autoimmune diseases mediated by either protein, reducing the need for separate compound development programs
2Reliability
If novel acylsulfonamide compounds are synthesized to inhibit KAT6A, then therapeutic potential for cancer and autoimmune diseases is improved, but manufacturing precision and production challenges increase
Solution Approach 1:
The synthesis strategy segments the complex acylsulfonamide molecule into manageable components: a core acylsulfonamide structure with separately optimized substituent groups. This modular approach allows independent synthesis and characterization of building blocks, improving manufacturing precision by breaking down the complex synthesis into controlled stages with intermediate purification steps
Solution Approach 2:
The patent employs intermediary compounds as synthetic precursors and building blocks in the multi-step synthesis pathway. These intermediates serve as stable, characterizable milestones that facilitate quality control and manufacturing precision by providing checkpoint verification points during the synthesis process
Data Source
AI summary
The present disclosure describes acylsulfonamide compounds of Formula (J), and pharmaceutically acceptable salts, compositions, methods, and uses thereof. Such compounds are believed to be therapeutically useful as KAT6A inhibitors particularly in the treatment and/or prevention of diseases and disorders mediated by KAT6A in a subject.